(Q36390901)

13 August 2017

1 reference

title

Optimizing antibiotic treatment for ventilator-associated pneumonia (English)

1 reference

13 August 2017

0 references

1 reference

5

Marin H Kollef

1 reference

13 August 2017

Scott T Micek

1

1 reference

13 August 2017

Timothy J Heuring

series ordinal

2

1 reference

13 August 2017

James M Hollands

series ordinal

3

1 reference

13 August 2017

Rina A Shah

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

26

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

204-213

1 reference

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pneumonia in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Implications of endotracheal tube biofilm for ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Ventilator-associated pneumonia due to Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Colonization of lower respiratory tract with anaerobic bacteria in mechanically ventilated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacokinetic population study to describe cefepime lung concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Penetration of aztreonam into human bronchial secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacodynamics of cefepime in patients with Gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Linezolid in VAP by MRSA: a better choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Experience with a clinical guideline for the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.204

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.2.204

1 reference

13 August 2017

1 reference